Animal model of Pancreatic Cancer

我们已经建立了LSL-Kras G12 D（条件性K-ras突变体）、LSL p53 R172 H（条件性p53突变体），Pdx-1-Cre（胰腺特异性Cre重组酶转基因）， NOS 2和IL-6缺陷小鼠。我们还产生了NOS 2缺陷型LSL-Kras G12 D小鼠。到 激活条件突变K-ras和p53等位基因这些小鼠与Pdx-1-Cre一起繁殖 小鼠将IL-6缺陷型小鼠与LSL-Kras G12 D（条件性K-ras突变体）杂交， 产生IL-6缺陷的条件性K-ras突变小鼠。激活后，Kras和p53 双突变小鼠中超过90%的小鼠将在3-6个月内发展PDAC。这些老鼠会 与那些缺乏NOS 2或IL-6或 用抗MIF抗体治疗。

We have established the colonies of LSL-Kras G12D (conditional K-ras mutant), LSL p53 R172 H (conditional p53 mutant), Pdx-1-Cre (pancreas-specific Cre-recombinase transgenic), NOS2- and IL-6 -deficient mice. We have also generated NOS2-deficient LSL-Kras G12D mice. To activate the conditional mutant K-ras and p53 alleles these mice are being bred with Pdx-1-Cre mice. IL-6 deficient mice are crossed with LSL-Kras G12D (conditional K-ras mutant) to generate IL-6-deficient conditional K-ras mutant mice. Following activation, the Kras and p53 double mutant mice will develop PDAC in 3-6 months in more than 90% of mice. These mice will be compared with those Kras and p53 double mutant mice that lack either NOS2 or IL-6 or are treated with anti-MIF antibody.